Accurate and comprehensive genomic insights are increasingly essential for the diagnosis, classification, and risk stratification of myeloid malignancies — spanning single nucleotide variants, gene fusions, and large chromosomal aberrations. Yet consolidating these layers of genomic data into routine clinical workflows remains a significant bottleneck for many laboratories.​

In this webinar, join Cecilia Lang, Biochemist and Head of Cytogenetics at Laboratorio de Especialidades Bioquímicas (LEB, Argentina), and Brandon Bullough, Product Marketing Director at SOPHiA GENETICS, as they explore how NGS-based molecular profiling with the SOPHiA DDM™ Myeloid Solution v2 (MYS2) can consolidate laboratory workflows and accelerate time-to-insights in the analysis of myeloid malignancies.​

Brandon Bullough will open with an overview of SOPHiA DDM™ MYS2, tracing the need that drove its development and what sets it apart as a comprehensive myeloid solution. Cecilia Lang will then share her team's real-world experience implementing SOPHiA DDM™ MYS2 at a cytogenetics-focused reference center in Latin America — including its practical impact on day-to-day workflows and her perspective on where the field is headed.​

Learning objectives​

• Understand the rationale behind the development of a comprehensive application for myeloid malignancies​
• Learn how SOPHiA DDM™ MYS2 has complemented and streamlined cytogenetic workflows at LEB​
• Explore its impact on the detection of chromosomal aberrations compared to standard cytogenetic methods​
• Discover patient cases where the comprehensive NGS profiling has a meaningful impact​
• Gain perspectives on the future of integrated molecular and cytogenetic analysis for diagnostic insights​

Speakers

Cecilia Lang
Head of Cytogenetics and FISH
Laboratorio de Especialidades Bioquimicas, LEB

Andrea Bender
Head of Molecular Biology
Laboratorio de Especialidades Bioquimicas, LEB

Brandon Bullough
Product Marketing Director, Blood Cancers
SOPHiA GENETICS

Real-world insights from Hospital Mário Penna

In this webinar, we explore how the MaxCare Program supported Hospital Mário Penna in implementing and adopting into routine two new NGS applications for the investigation of myeloid and lymphoid malignancies. The program empowered the local team to gain confidence in their results while assessing and establishing the analytical performance of the workflow.

Hospital Mário Penna shares their experience with SOPHiA GENETICS’ end-to-end implementation support, covering every step of the process—from strategic consultation and on-site training to data generation and analytical performance evaluation by the data science team, all tailored to the laboratory’s real-world context. The session concludes with the transition of these tests into routine practice, illustrated through two case studies: one in acute myeloid leukemia (AML) and the other in chronic lymphocytic leukemia (CLL).

Speakers:

Carolina Pereira de Souza Melo, PhD,
Researcher, Basic and Translational Oncology Research Laboratory, Instituto Mário Penna, Brazil

Gabrielle Martins Gonçalves, MSc,
SOPHiA GENETICS Implementation Scientist LATAM

Day: May 14th
Time: 11h BR/AR l 10h CL l 9h CO/PA l 8h MX/CR

En el marco del Día Internacional de la Mujer, este webinar presentará la trayectoria académica y profesional de la Dra. Carmen Alaez, reconocida líder en el campo de la genómica en América Latina. La sesión abordará los desafíos asociados a la implementación de metodologías avanzadas en el laboratorio clínico, así como el proceso de consolidación de la secuenciación de próxima generación como herramienta estratégica para el diagnóstico de enfermedades raras.

Se analizarán también los retos específicos del contexto latinoamericano, como: el acceso a tecnologías y fortalecimiento de capacidades diagnósticas, así como también estos han sido enfrentados y superados a lo largo de los años. La Dra. Alaez profundizará en estos desafíos, compartiendo una visión integral de su trayectoria en genómica del cáncer hereditario y diagnóstico molecular, así como del liderazgo femenino en el desarrollo de la medicina genómica en la región.

Ponente:
Dra. Carmen Alaez
Jefe de Departamento de Diagnóstico Genómico
INMEGEN, Mexico

Doctora en Ciencias Químicobiológicas por el IPN, es Investigadora en Ciencias Médicas “C” y Jefa del Laboratorio de Diagnóstico Genómico del INMEGEN, miembro del SNII Nivel II. Desde 2015 lidera investigaciones en genómica del cáncer y diagnóstico de enfermedades hereditarias, con enfoque en cáncer de mama y ovario, tumores sólidos, leucemia pediátrica y enfermedades mendelianas. Cuenta con 75 publicaciones, 28 capítulos de libro y cerca de 875 citas. Ha dirigido 15 tesis y ha recibido 39 premios y distinciones.

Hora:
10:00 AM (Mexico)
11:00 AM (Colombia)
1:00 PM (Brazil / Argentina)